{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:51:30Z","timestamp":1792205490337,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2466-14-4","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T00:01:25Z","timestamp":1390003285000},"source":"Crossref","is-referenced-by-count":60,"title":["A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study"],"prefix":"10.1186","volume":"14","author":[{"given":"Kenneth R","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Michael","family":"Beeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"D\u2019Urzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nutbrown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Henley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Overend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"key":"456_CR1","volume-title":"Global strategy for the diagnosis, management and prevention of COPD","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013","year":"2013","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013: Global strategy for the diagnosis, management and prevention of COPD. 2013, \n                    http:\/\/www.goldcopd.org\/guidelines-global-strategy-for-diagnosis-management.html\n                    \n                  ,"},{"issue":"15","key":"456_CR2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359 (15): 1543-1554. 10.1056\/NEJMoa0805800.","journal-title":"N Engl J Med"},{"key":"456_CR3","volume-title":"Bretaris Genuair (aclidinium bromide) summary of product characteristics","author":"European Medicines Agency (EMA)","year":"2013","unstructured":"European Medicines Agency (EMA): Bretaris Genuair (aclidinium bromide) summary of product characteristics. 2013, \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002706\/WC500132732.pdf\n                    \n                  ,"},{"key":"456_CR4","volume-title":"Tudorza pressair (aclidinium bromide) US prescribing information","author":"Food and Drug Administration (FDA)","year":"2013","unstructured":"Food and Drug Administration (FDA): Tudorza pressair (aclidinium bromide) US prescribing information. 2013, \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202450s000lbl.pdf\n                    \n                  ,"},{"key":"456_CR5","volume-title":"Seebri Breezhaler (glycopyrronium bromide) Summary of Product Characteristics","author":"European Medicines Agency (EMA)","year":"2013","unstructured":"European Medicines Agency (EMA): Seebri Breezhaler (glycopyrronium bromide) Summary of Product Characteristics. 2013, \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002430\/WC500133769.pdf\n                    \n                  ,"},{"key":"456_CR6","volume-title":"Media release: Novartis receives European commission approval for once-daily Seebri\u00ae Breezhaler\u00ae as maintenance COPD treatment in the EU","author":"Novartis Global","year":"2012","unstructured":"Novartis Global: Media release: Novartis receives European commission approval for once-daily Seebri\u00ae Breezhaler\u00ae as maintenance COPD treatment in the EU. 2012, \n                    http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1645116.shtml\n                    \n                  ,"},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2147\/COPD.S32451","volume":"7","author":"KM Beeh","year":"2012","unstructured":"Beeh KM, Singh D, Di SL, Drollmann A: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012, 7: 503-13.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1465-9921-12-156","volume":"12","author":"A D\u2019Urzo","year":"2011","unstructured":"D\u2019Urzo A, Ferguson GT, Van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011, 12: 156-10.1186\/1465-9921-12-156.","journal-title":"Respir Res"},{"issue":"5","key":"456_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1183\/09031936.00040712","volume":"40","author":"E Kerwin","year":"2012","unstructured":"Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012, 40 (5): 1106-1114. 10.1183\/09031936.00040712.","journal-title":"Eur Respir J"},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1465-9921-13-52","volume":"13","author":"KM Beeh","year":"2012","unstructured":"Beeh KM, Beier J, Donohue JF: Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res. 2012, 13: 52-10.1186\/1465-9921-13-52.","journal-title":"Respir Res"},{"key":"456_CR11","volume-title":"Global strategy for the diagnosis, management and prevention of COPD","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2010","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of COPD. 2010, \n                    http:\/\/www.goldcopd.org\/Guidelines\/guideline-2010-gold-report.html\n                    \n                  ,"},{"issue":"1","key":"456_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.05.00034505","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, et al: General considerations for lung function testing. Eur Respir J. 2005, 26 (1): 153-161. 10.1183\/09031936.05.00034505.","journal-title":"Eur Respir J"},{"issue":"1","key":"456_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF: Minimal clinically important differences in COPD lung function. COPD. 2005, 2 (1): 111-124. 10.1081\/COPD-200053377.","journal-title":"COPD"},{"issue":"2","key":"456_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","volume":"21","author":"TJ Witek Jr","year":"2003","unstructured":"Witek TJ, Mahler DA: Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003, 21 (2): 267-272. 10.1183\/09031936.03.00068503a.","journal-title":"Eur Respir J"},{"issue":"1","key":"456_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW: St. George\u2019s Respiratory Questionnaire: MCID. COPD. 2005, 2 (1): 75-79. 10.1081\/COPD-200050513.","journal-title":"COPD"},{"issue":"7","key":"456_CR16","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.rmed.2012.03.012","volume":"106","author":"JF Donohue","year":"2012","unstructured":"Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G: A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012, 106 (7): 970-979. 10.1016\/j.rmed.2012.03.012.","journal-title":"Respir Med"},{"issue":"2","key":"456_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","volume":"182","author":"JF Donohue","year":"2010","unstructured":"Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, et al: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010, 182 (2): 155-162. 10.1164\/rccm.200910-1500OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"456_CR18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2165\/00003495-200969090-00005","volume":"69","author":"NA Hanania","year":"2009","unstructured":"Hanania NA, Boota A, Kerwin E, Tomlinson L, Is-Mize K: Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009, 69 (9): 1205-1216. 10.2165\/00003495-200969090-00005.","journal-title":"Drugs"},{"issue":"3","key":"456_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.rmed.2011.09.004","volume":"106","author":"KS Jung","year":"2012","unstructured":"Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD: Comparison of tiotropium plus fluticasone propionate\/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012, 106 (3): 382-389. 10.1016\/j.rmed.2011.09.004.","journal-title":"Respir Med"},{"issue":"2","key":"456_CR20","first-page":"262","volume":"10","author":"V Higgins","year":"2013","unstructured":"Higgins V, Broomfield S, Pollard R, Fermer S: Impact of morning symptoms on the working lives of COPD patients [abstract]. COPD. 2013, 10 (2): 262-","journal-title":"COPD"},{"issue":"8","key":"456_CR21","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1185\/03007990903103006","volume":"25","author":"MR Partridge","year":"2009","unstructured":"Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009, 25 (8): 2043-2048. 10.1185\/03007990903103006.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"456_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/thx.2007.086041","volume":"63","author":"J Bourbeau","year":"2008","unstructured":"Bourbeau J, Bartlett SJ: Patient adherence in COPD. Thorax. 2008, 63 (9): 831-838. 10.1136\/thx.2007.086041.","journal-title":"Thorax"},{"issue":"11","key":"456_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/thx.2009.113662","volume":"64","author":"J Vestbo","year":"2009","unstructured":"Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009, 64 (11): 939-943. 10.1136\/thx.2009.113662.","journal-title":"Thorax"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-14-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T04:05:05Z","timestamp":1548216305000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-14-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-14-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,17]]},"article-number":"4"}}